Duloxetine in treatment of anxiety symptoms associated with depression

Depression and Anxiety

Volumn 18, Issue 2, 2003, Pages 53-61

  Dunner, David L ^a   Goldstein, David J ^b,c   Mallinckrodt, Craig ^d   Lu, Yili ^d   Detke, Michael J ^b,d,e,f  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PRN Consulting   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e MCLEAN HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anxiety; Depression; Duloxetine; Hamilton Anxiety Rating Scale; Hamilton Depression Rating Scale

Indexed keywords

DULOXETINE; FLUOXETINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ANXIETY DISORDER; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; EMOTION; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MOOD; PAIN; PRIORITY JOURNAL; REMISSION; REVIEW; SOMATIZATION; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; THIOPHENES;

EID: 0141731324     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.10122     Document Type: Review

References (35)

1. Ayd FJ Jr. 1984. Is it anxiety or depression? South Med J 77:1269-1272.
2. Bjelland I, Dahl AA. 1999. Angst og deprejon-en vanlig blanding. Tidsskr Nor Lägeforen 119:3277-3280.
3. Boyer P, et al. 2000. Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression. J Clin Pharm Ther 25:363-371.
4. Bymaster FP, et al. 2001. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880.
5. Chalon S, et al. 2002. The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition. Neuropsychopharmacology 26:698-701.
6. Cornwall PL, Scott J. 1997. Partial remission in depressive disorders. Acta Psychiatr Scand 95:265-271.
7. Detke MJ, et al. 2002a. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308-315.
8. Detke MJ, et al. 2002b. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatry Res 36:383-390.
9. Di Nardo P, Barlow D. 1990. Syndrome and symptom co-occurrence in the anxiety disorders. In: Maser J, Cloninger CR, editors. Washington, DC: American Psychiatric Press. p 205-230.
10. Fawcett J, Kravitz HM. 1983. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 44:8-11.
11. Fawcett J, et al. 1990. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 147:1189-1194.
12. Garrison GD, Levin GM. 2000. Factors affecting prescribing of the newer antidepressants. Ann Pharmacother 34:10-14.
13. Goldstein DJ, et al. 2002a. Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. Eur Neuropsychopharmacol 12(Suppl. 2):S43-S44.
14. Goldstein DJ, et al. 2002b. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J Clin Psychiatry 63:225-231.
15. Gorman JM, Papp LA. 2000. Efficacy of venlafaxine in mixed depression-anxiety states. Depress Anxiety 12:77-80.
16. Grunhaus, L, et al. 1988. Major depressive disorder and panic disorder. Effects of comorbidity on treatment outcome with antidepressant medications. Clin Neuropharmacol 11:454-461.
17. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
18. Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
19. Hudson JI, Pope HG Jr. 1990. Affective spectrum disorder: Does antidepressant response identify a family of disorders with a common pathophysiology? Am J Psychiatry 147:552-564.
20. Khan A, et al. 2003. Placebo Response and Antidepressant Clinical Trial outcome. J Nervous Mental Dis 19:211-218.
21. Murray CJ, Lopez AD. 1996. The Global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press.
22. Nemeroff CB, et al. 2002. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36:106-132.
23. Nierenberg AA, Wright EC. 1999. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 60(Suppl. 22):7-11.
24. Paykel ES, et al. 1995. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25:1171-1180.
25. Physician's Desk Reference. 2002. Montvale, NJ: Medical Economics Company.
26. Rickels K, et al. 1993. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50:884-895.
27. Roy-Byrne PP. 1996. Generalized anxiety and mixed anxiety-depression: Association with disability and health care utilization. J Clin Psychiatry 57(Suppl. 7):86-91.
28. Rudolph RL, Entsuah R, Chitra R. 1998. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 18:136-144.
29. Schapira K, et al. 1972. The prognosis of affective disorders: The differentiation of anxiety states from depressive illnesses. Br J Psychiatry 121:175-181.
30. Schwarz R, et al. 2001. Angst und depreeivtät in der über 60-jahrigen Allgemeinhevölkerung. Dtsch Med Wschr 126:611-615.
31. Sheehan DV, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl. 20):22-33.
32. Stahl SM. 1999. Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antidepressant therapy. J Clin Psychiatry 60:213-214.
33. Stein MB, et al. 1995. Mixed anxiety-depression in a primary-care clinic. J Affect Disord 34:79-84.
34. Van Valkenburg C, et al. 1984. Anxious depressions: Clinical, family history, and naturalistic outcome - comparisons with panic and major depressive disorders. J Affect Disord 6:67-82.
35. Zung WW, et al. 1990. The comorbidity of anxiety and depression in general medical patients: A longitudinal study. J Clin Psychiatry 51(Suppl):77-80.